Edap Tms (NASDAQ:EDAP) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Thursday, ValuEngine reports.
Other equities analysts have also recently issued research reports about the company. TheStreet cut Edap Tms from a “b-” rating to a “d+” rating in a research note on Monday, June 17th. Zacks Investment Research upgraded Edap Tms from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Finally, HC Wainwright set a $7.00 price target on Edap Tms and gave the company a “buy” rating in a report on Tuesday, June 11th.
NASDAQ:EDAP traded down $0.05 on Thursday, hitting $3.05. 34,666 shares of the company’s stock traded hands, compared to its average volume of 273,204. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.97 and a current ratio of 2.40. Edap Tms has a 1 year low of $1.35 and a 1 year high of $5.42. The firm’s 50-day simple moving average is $2.76. The firm has a market capitalization of $88.45 million, a P/E ratio of 152.50 and a beta of 1.75.
Edap Tms (NASDAQ:EDAP) last released its earnings results on Wednesday, May 15th. The medical equipment provider reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. Edap Tms had a negative return on equity of 1.13% and a negative net margin of 0.36%. The company had revenue of $11.50 million for the quarter, compared to analysts’ expectations of $13.25 million. Analysts predict that Edap Tms will post 0.08 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Edap Tms stock. Hilton Capital Management LLC purchased a new stake in shares of Edap Tms SA (NASDAQ:EDAP) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 25,000 shares of the medical equipment provider’s stock, valued at approximately $75,000. Hilton Capital Management LLC owned about 0.09% of Edap Tms at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.32% of the company’s stock.
Edap Tms Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Further Reading: Should You Consider an Index Fund?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.